The specification generally relates to compounds of Formula(I):and pharmaceutically acceptable salts thereof, whereR1has the meanings defined herein. The specification also relates to the use of compounds of Formula(I)and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof； and kits comprising such compounds and salts.本發明大體上係關於式(I)化合物： 及其醫藥學上可接受之鹽，其中R1具有本文中所定義之含義。本說明書亦關於式(I)化合物及其鹽用於治療或預防ATM介導之疾病，包括癌症之用途。本發明進一步係關於包含經取代之咪唑并[4,5-c]喹啉-2-酮化合物及其醫藥學上可接受之鹽的醫藥組合物；及包含此類化合物及鹽之套組。
